<DOC>
	<DOCNO>NCT00089674</DOCNO>
	<brief_summary>This study evaluate AMG 162 treatment bone loss subject undergoing Androgen-Deprivation Therapy Non-metastatic Prostate Cancer .</brief_summary>
	<brief_title>AMG 162 Treatment Bone Loss Subjects Undergoing Androgen-Deprivation Therapy Non-metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Other criterion also apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Bone Loss Prostate Cancer</keyword>
	<keyword>Treatment bone loss patient undergo androgen deprivation therapy ( ADT ) non-metastatic prostate cancer ( PC ) .</keyword>
</DOC>